Evolution of viral biomarkers in predicting outcomes of chronic hepatitis B patients: From DNA to surface antigen

Tzu-Chi Medical Journal

Tai-Chung Tsenga¹ 

关键词: HBsAg;    HBV;    HCC;    Hepatitis;    qHBsAg;   

DOI  :  

学科分类：医学（综合）

来源: Wolters Kluwer Medknow Publications

【 摘 要 】

Quantification of hepatitis B virus (HBV) DNA and quantitative hepatitis B surface antigen (HBsAg) have improved our understanding and management of chronic hepatitis B (CHB). Both HBV DNA and HBsAg levels are highest in the immune tolerance phase, start to decline during the immune clearance phase, and further decline after hepatitis B e antigen (HBeAg) seroconversion. These levels are lowest in the inactive carrier state but rise again in patients who develop HBeAg-negative hepatitis. Previous studies have shown that an HBV DNA level ≥2000 IU/mL is associated with high risks of hepatocellular carcinoma, liver cirrhosis, and hepatitis activity, whereas a lower HBV DNA level is associated with a better chance of HBsAg loss, which is very close to a clinical cure for HBV infection. Recent studies further suggested that HBsAg level is not only a better predictor of HBsAg loss compared with the HBV DNA level, but also can complement the HBV DNA level in predicting HBV-related adverse events in patients with an HBV DNA level.

【 授权许可】

CC BY-NC-SA